Literature DB >> 33536349

Tumor microenvironment characterization in triple-negative breast cancer identifies prognostic gene signature.

Yan Qin1, Jiehua Deng1, Lihua Zhang1, Jiaxing Yuan1, Huawei Yang1, Qiuyun Li1.   

Abstract

We aimed to elucidate the landscape of tumor microenvironment (TME) in triple-negative breast cancer (TNBC). Cohorts from Gene Expression Omnibus database (N = 107) and METABRIC (N = 299) were used as the training set and validation set, respectively. TME was evaluated via single-sample gene set enrichment analysis, and unsupervised clustering was used for cluster identification. Consequently, TNBC was classified into two distinct TME clusters (Cluster 1 and Cluster 2) according to predefined immune-related terms. Cluster 1 was characterized by low immune infiltration with poor prognosis; whereas, Cluster 2 was characterized by high immune infiltration with better survival probability. Further, Cluster 1 had larger tumor volumes, while Cluster 2 had smaller tumor volumes. Finally, a TME signature for prognosis stratification in TNBC was developed and validated. In summary, we comprehensively evaluated the TME of TNBC and constructed a TME signature that correlated with prognosis. Our results provide new insights for the immunotherapy of TNBC.

Entities:  

Keywords:  immune checkpoint; triple-negative breast cancer; tumor microenvironment

Year:  2021        PMID: 33536349      PMCID: PMC7950290          DOI: 10.18632/aging.202478

Source DB:  PubMed          Journal:  Aging (Albany NY)        ISSN: 1945-4589            Impact factor:   5.682


  46 in total

1.  Adjusting batch effects in microarray expression data using empirical Bayes methods.

Authors:  W Evan Johnson; Cheng Li; Ariel Rabinovic
Journal:  Biostatistics       Date:  2006-04-21       Impact factor: 5.899

Review 2.  Circulating and disseminated tumour cells - mechanisms of immune surveillance and escape.

Authors:  Malte Mohme; Sabine Riethdorf; Klaus Pantel
Journal:  Nat Rev Clin Oncol       Date:  2016-09-20       Impact factor: 66.675

3.  Disrupted expression of CXCL5 in colorectal cancer is associated with rapid tumor formation in rats and poor prognosis in patients.

Authors:  Frank M Speetjens; Peter J K Kuppen; Maro H Sandel; Anand G Menon; Danny Burg; Cornelis J H van de Velde; Rob A E M Tollenaar; Hans J G M de Bont; J Fred Nagelkerke
Journal:  Clin Cancer Res       Date:  2008-04-15       Impact factor: 12.531

Review 4.  Triple negative breast cancer in Asia: An insider's view.

Authors:  Chao Wang; Shreya Kar; Xianning Lai; Wanpei Cai; Frank Arfuso; Gautam Sethi; Peter E Lobie; Boon C Goh; Lina H K Lim; Mikael Hartman; Ching W Chan; Soo C Lee; Sing H Tan; Alan P Kumar
Journal:  Cancer Treat Rev       Date:  2017-11-10       Impact factor: 12.111

Review 5.  Bispecific T-cell engaging antibodies for cancer therapy.

Authors:  Patrick A Baeuerle; Carsten Reinhardt
Journal:  Cancer Res       Date:  2009-06-09       Impact factor: 12.701

6.  Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer.

Authors:  Gabriela Bindea; Bernhard Mlecnik; Marie Tosolini; Amos Kirilovsky; Maximilian Waldner; Anna C Obenauf; Helen Angell; Tessa Fredriksen; Lucie Lafontaine; Anne Berger; Patrick Bruneval; Wolf Herman Fridman; Christoph Becker; Franck Pagès; Michael R Speicher; Zlatko Trajanoski; Jérôme Galon
Journal:  Immunity       Date:  2013-10-17       Impact factor: 31.745

7.  ANKRD22 promotes progression of non-small cell lung cancer through transcriptional up-regulation of E2F1.

Authors:  Jun Yin; Wenfan Fu; Lu Dai; Zeyong Jiang; Hongying Liao; Wenbin Chen; Lei Pan; Jian Zhao
Journal:  Sci Rep       Date:  2017-06-30       Impact factor: 4.379

8.  PD-L1 Expression and Immune Cell Infiltration in Gastroenteropancreatic (GEP) and Non-GEP Neuroendocrine Neoplasms With High Proliferative Activity.

Authors:  Martina Ferrata; Arno Schad; Stefanie Zimmer; Thomas J Musholt; Katharina Bahr; Julian Kuenzel; Sven Becker; Erik Springer; Wilfried Roth; Matthias M Weber; Christian Fottner
Journal:  Front Oncol       Date:  2019-05-07       Impact factor: 6.244

Review 9.  Recent advances in triple negative breast cancer: the immunotherapy era.

Authors:  Antonio Marra; Giulia Viale; Giuseppe Curigliano
Journal:  BMC Med       Date:  2019-05-09       Impact factor: 8.775

10.  An easy-to-use scoring system to estimate the survival of patients irradiated for bone metastases from lung cancer.

Authors:  Dirk Rades; Rapha Haus; Stefan Janssen; Steven E Schild
Journal:  Transl Lung Cancer Res       Date:  2020-08
View more
  3 in total

1.  A Novel Seven Gene Signature-Based Prognostic Model to Predict Distant Metastasis of Lymph Node-Negative Triple-Negative Breast Cancer.

Authors:  Wenting Peng; Caijin Lin; Shanshan Jing; Guanhua Su; Xi Jin; Genhong Di; Zhiming Shao
Journal:  Front Oncol       Date:  2021-09-16       Impact factor: 6.244

2.  Prognostic Capability of TNBC 3-Gene Score among Triple-Negative Breast Cancer Subtypes.

Authors:  Jhajaira M Araujo; Gabriel De la Cruz-Ku; Melanie Cornejo; Franco Doimi; Richard Dyer; Henry L Gomez; Joseph A Pinto
Journal:  Cancers (Basel)       Date:  2022-09-01       Impact factor: 6.575

3.  Systematic evaluation of tumor microenvironment and construction of a machine learning model to predict prognosis and immunotherapy efficacy in triple-negative breast cancer based on data mining and sequencing validation.

Authors:  Qiheng Gou; Zijian Liu; Yuxin Xie; Yulan Deng; Ji Ma; Jiangping Li; Hong Zheng
Journal:  Front Pharmacol       Date:  2022-09-26       Impact factor: 5.988

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.